Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	June 2, 2022
Length of Meeting:	2 hours
Location of Meeting:	DMAS Board Room 102

Members Present:
John Morgan, MD, Chief Clinical Innovation Officer, Chair
Rachel Cain, PharmD
Elizabeth Gaughan, MD
Kathryn Reid, PhD
Kristi Fowler, RPh
Matthew Estes, PharmD
Melissa Chouinard, MD
Michele Thomas, PharmD
Seth Brant, MD
Wendy Nash, PharmD

Members Not Present:
Denese Gomes, NP
Denise Lowe, PharmD
Randy Ferrance, MD

DMAS Attendees:
MaryAnn McNeil, RPh, Pharmacy Manager
Nettie Emmelhainz, PharmD, Senior Pharmacy Policy and Data Analyst
JoeMichael Fusco, PharmD, Common Core Formulary Pharmacist
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Magellan Health Services
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Health Services
Jeni Hodzic, CPhT, Senior Account Management Specialist, Magellan Health Services

Visitors:
Jon Siler
Arden Arslanyan
Mark Stephens

Ronda Fudge
David Roy
John Stancil
Mike Boskello
Tanner Odom
Laurie Mauthe

Call to Order and Introductions

Dr. John Morgan welcomed and thanked everyone for attending the DUR meeting.

Dr. Morgan called the meeting to order at 1:00 pm.

Dr. Rachel Cain introduced one new DUR Board Member:

- Elizabeth Gaughan, MD – Oncologist, University of Virginia

Minutes – March 10, 2022

Dr. Michele Thomas motioned to approve the March 10, 2022 meeting minutes as submitted. Dr. Cain seconded the motion.

New Drugs

The DUR Board reviewed Rezurock™ (belumosudil). They discussed the impact report, the utilization report, and the service authorization (SA) criteria for Rezurock™. After much discussion by the board, Kristi Fowler motioned to accept the service authorization criteria with the following changes; add the question “Prescribed by or in consultation with an oncologist or transplant specialist?”, revise question number 2 to “Is the member post-allogeneic stem cell transplant?”, revise question number 4 to “Does the member have post-transplant lymphoproliferative disease?”, remove questions number 5, 6, 7, and 8 from the initial approval criteria section, remove questions 10 and 11 and add “Has the member been evaluated by an oncologist or transplant specialist, or the provider is working in conjunction with an oncologist or transplant specialist, in the last 6 months?” under the renewal criteria section and add a quantity limit of 60 for Rezurock™, a maximum of 2 tablets per day. Dr. Thomas seconded the motion.

Physician Administered Drugs (PADs)

DMAS is in the process of developing a physician administered program which will be followed by the DUR Board.

- **Aduhelm™ (aducanumab-avwa)**
  Aduhelm™ will be tabled and reviewed at the next DUR meeting in September 2022.

- **Atypical Antipsychotics, Long Acting Injectables (Closed Class)**
  The DUR Board reviewed the current clinical criteria for Antipsychotics in Children Younger than 18 Years Old.

MRx Pipeline and DUR Quarterly Newsletter- The April 2022 MRx Pipeline Report and the March 2022 DUR Quarterly Newsletter were available on the DUR Webportal for review.

Topics for Discussion

Concurrent Use of Opioids and Benzodiazepines – The DUR Board reviewed Concurrent Use of Opioids and Benzodiazepines reports for FFS and MCOs. The Board expressed an interest in reviewing the Patient Utilization Management and Safety (PUMS) program to look for any changes, which may have occurred between its implementation and present date.

Concurrent Use of Opioids and Antipsychotics – The DUR Board reviewed Concurrent Use of Opioids and Antipsychotics reports for FFS and MCOs.

Antipsychotic Medications in Children – The DUR Board reviewed Antipsychotic Medications in Children reports for FFS and MCOs. The Board expressed an interest in a review of the steps taken by DMAS and Magellan to make sure the criteria, indications, and call center approval/denial flow process are appropriate and up-to-date for antipsychotic medications in children.

Reports

ProDUR

The DUR Board reviewed the ProDUR reports. Magellan is working on a new version of the ProDUR Top Encounters by Problem Type Report to show only the severity level 1 ProDUR edits.

RetroDUR

I. **Recent RetroDUR Activity**

The DUR Board reviewed the Recent RetroDUR Activity reports.

Dr. Cain reached out to CMS for clarification on required RetroDUR activity. CMS responded that State Medicaid DUR programs are not required to send monthly RetroDUR letters to providers but are required to communicate in some way with those identified providers. In the future, DMAS will be sending a variety of letters including informational letters.

II. RetroDUR Criteria Estimates

The Criteria Exception Estimates Reports were provided in the binder for review. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan.

The DUR Board expressed an interest in looking at the use of Latuda® without an FDA approved indication in history for lettering.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. Magellan is in the process of updating the Top 25 Drugs Ranked by Claim Count and the Top 25 Drugs Ranked by Payment Amount to remove the medical claims and only include pharmacy claims.

Next DUR Meeting

September 8, 2022

Dr. Morgan motioned to adjourn the meeting. Dr. Thomas seconded the motion.
Meeting adjourned at 3:00 pm.